Acorda loss widens

November

Acorda Therapeutics Inc., the biopharmaceutical company in Hawthorne, lost $8.5 million, or 30 cents a share, during the third quarter, compared with a loss of $7.2 million, or .37 a share, a year earlier, the company reported this morning. Sales were up to $10.44 million from $6.16 million. Acorda markets Zanaflex, a treatment for involuntary muscle movements caused by multiple sclerosis and spinal injuries. The company is conducting tests on Famipridine-SR, a drug to help patients with MS walk. The companyÃ¢â‚¬â„¢s shares closed yesterday at $20.38, up 6 cents, and have risen 28.7 percent on the year.

This entry was posted on Tuesday, November 6th, 2007 at 10:20 am by Allan Drury.
You can follow any responses to this entry through the RSS 2.0 feed.
Print | Email

It is a condition of your use of the comment features associated with the blogs that you do not: Use the site to post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including without limitation any transmissions constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or international law. You alone are responsible for the material you post or send. Refer to the Terms of Service.

Business in the Burbs

Movers, shakers and newsmakers